Validated LC-MS/MS method for quantification of gabapentin in human plasma: Application to pharmacokinetic and bioequivalence studies in Korean volunteers

Biomedical Chromatography

Volumn 21, Issue 8, 2007, Pages 829-835

  Park, Jin Hee ^a   Jhee, Ok Hwa ^b   Park, Song Hee ^a   Lee, Jung Sik ^a   Lee, Min Ho ^c   Shaw, Leslie M ^d   Kim, Kwang Hyun ^e   Lee, Jong Ho ^f   Kim, Yong Seok ^a   Kang, Ju Seop ^a  

^a Hanyang University   (South Korea)

^b Kongju National University   (South Korea)

^c Hanyang University College of Medicine   (South Korea)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Bio Mediang Co   (South Korea)

^f AmorePacific Corporation   (South Korea)

Author keywords

Bioequivalence study; Gabapentin; LC MS MS; Pharmacokinetics

Indexed keywords

LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHARMACOKINETICS; PLASMA (HUMAN);

BIOEQUIVALENCE STUDY; CROSSOVER DESIGN; GABAPENTIN; HUMAN PLASMAS; LC-MS-MS; LC.MS/MS; PHARMACOKINETIC STUDIES; SIMPLE++; SPECTROMETRIC METHODS; TANDEM MASS SPECTROMETRIC;

ACETONITRILE;

ACETONITRILE; ALPHA AMINOCYCLOHEXANEPROPIONIC ACID; AMMONIUM ACETATE; GABAPENTIN; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; COLUMN CHROMATOGRAPHY; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG STRUCTURE; HUMAN; HUMAN EXPERIMENT; KOREA; LINEAR SYSTEM; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; PRECIPITATION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; VALIDATION STUDY; VOLUNTEER;

EID: 34547662485     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.826     Document Type: Article

References (30)

1. Beydoun A, Fakhoury T, Nasreddine W and Abou-Khalil B. Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy. Epilepsia 1998; 39: 188.
2. Bockbrader HN. Clinical pharmacokinetics of gabapentin. Drugs Today 1995; 31: 613.
3. Borrey DC, Godderis KO, Engelrelst VI, Bernard DR and Langlois MR. Quantitative determination of vigabatrin ana gabapentin in human serum by gas chromatography-mass chromatography. Clinica Chimica Acta 2005; 354: 147.
4. Chen M, Shah V, Patnaik R, Adams W, Hussain A, Conner D, Mehta M, Malinowski H, Lazor J, Huang S, Hare D, Lesko L, Sporn D and Williams R. Bioavailability and bioequivalence: an FDA regulatory overview. Pharmaceutical Research 2001; 18: 1645.
5. Gambelunghe C, Mariucci G, Tantucci M and Ambrosini MV. Gas chromatography-tandem mass spectrometry analysis of gabapentin in serum. Biomedical Chromatography 2005; 19: 63.
6. Gareri P, Gravina T. Ferreri G and De Sarro G. Treatment of epilepsy in the elderly. Progress in Neurobiology 1999; 58: 389.
7. 18 column. Clinical Chemistry 2002; 48: 2259.
8. Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M and Bockbrader HN. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Research 2000, 40: 123.
9. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. USDHHS, FDA, CDER, CVM, 2001.
10. Hooper WD, Kavanagh MC and Dickinson RG. Determination of gabapentin in plasma and urine by capillary column gas chromatography. Journal of Chromatography 1990; 529: 167.
11. Hyder AA, Human D, Crawley F, IJesselmuiden C, Singer PA and Benatar SR. Revised Declaration of Helsinki. British Medical Journal 2001; 323: 283.
12. Ifa DR, Falci M, Moraes ME, Bezerra FAF, Moraes MO and de Nucci G. Gabapentin quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study. Journal of Mass Spectrometry 2001; 36: 188.
13. Jemal M. High-throughput quantitative bioanalysis by LC/MS/MS. Biomedical Chromatography 2000; 14: 422.
14. Ji HY, Jeong DW, Kim YH, Kim H-H, Yoon YS, Lee KC and Lee HS. Determination of gabapentin inn human plasma using hydrophilic interaction liquid chromatography with tandem mass spectrometry. Rapid Communications in Mass Spectrometry 2006; 20: 2127.
15. Jiang Q and Li S. Rapid high-performance liquid chromatographic determination of serum gabapentin. Journal of Chromatography B 1999; 727: 119.
16. Lensmeyer GL, Kempf T, Gidal B and Weibe D. Optimized method for determination of gabapentin in serum by HPLC. Therapeutic Drug Monitoring 1995; 17: 251.
17. McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology 1994; 44: S17.
18. McLean MJ. Gabapentin in the management of convulsive disorders. Epilepsia 1999; 40: S39.
19. Quellet D, Bockbrader HN, Wesche DL, Shapiro DY and Garofalo E. Population pharmacokinetics of gabapentin in infants and children. Epilepsy Research 2001; 47: 229.
20. Ramakrishna NVS, Vishwottam KN, Koteshwara M, Manoj S, Santosh M, Chidambara J, Sumatha B and Varma DP. Rapid quantification of gabapentin in human plasma by liquid chromatography/tandem mass spectrometry. Journal of Pharmaceutical Biomededical Analysis 2006; 40: 360.
21. Shargel I, Yu-Pong S and Yu A. Applied Biopharmaceutics and Pharmacokinetics: Bioavailability and Bioequivalence, 5th edn. McGraw-Hill: New York, 2005; 453.
22. Sivenius J, Kalviainen R, Ylinen A and Riekkinen P. Double-blind study of gabapentin in the treatment of partial seizures. Epilepsia 1991; 32: 539.
23. Stewart BH, Kagler AR, Thompson PR and Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharmaceutical Research 1993; 10: 276.
24. Taylor CP. Gabapentin: mechanisms of action. In: Levy RH, Mattson RH and Melodrum BS (eds). Antiepileptic Drugs, 4th edn. Raven Press: New York, 1995; 829.
25. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990; 335: 1114.
26. US Gabapentin Study Group. The long-term safety and efficacy of ganapentin(Neurontin®) as add-on therapy in drug-resistant partial epilepsy. Epilepsy Research 1994; 18: 67.
27. Vollmer KO, von Hodenberg A and Kölle EU. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittel-Forschung 1983; 36: 3.
28. Walker MC and Patsalos PN. Clinical pharmacokinetics of new antiepileptic drugs. Pharmacology and Therapeutics 1995; 67: 351.
29. Wolf CE, Saady JJ and Poklis A. Determination of gabapentin in serum using solid-phase extraction and gas-liquid chromatography. Journal of Analytical Toxicology 1996; 20: 498.
30. Zhu Z and Neirinck L. High-performance liquid chromatographic method for the determination of gabapentin inhuman plasma. Journal of Chromatography B 2002; 779: 307.